ð åèç
å¿
è â Zika
- ssRNA flavivirus
- 2015-2016 Americas epidemic
- Aedes aegypti primary vector
- Sexual transmission unique (semen 6+ months)
- Congenital Zika Syndrome: microcephaly + brain calcifications + arthrogryposis + ocular
- GBS post-Zika documented association
å¿
è â Zika Diagnosis
- PCR blood (first 5d) + urine (up to 14d)
- IgM (cross-reacts with dengue)
- PRNT for confirmation
å¿
è â Zika Pregnancy
- Avoid travel to endemic
- Condoms ⥠3 mo post-Zika exposure
- Defer pregnancy 3-6 mo
å¿
è â Chikungunya
- ssRNA alphavirus
- Aedes aegypti / albopictus
- âTo walk bent overâ â severe polyarthralgia
- Chronic arthralgia 30-60% persists weeks-years
- 2024 Brazil + Paraguay severe epidemic
å¿
è â Chikungunya vs Dengue vs Zika
| Joint pain |
Moderate |
Severe + prolonged |
Mild |
| Hemorrhage |
Severe |
Rare |
Rare |
| Microcephaly |
No |
No |
YES |
| GBS |
Rare |
Rare |
Documented |
| Vaccine |
Dengvaxia, Qdenga |
Ixchiq (2023) |
None licensed |
å¿
è â Ixchiq Vaccine (FDA 2023)
- First chikungunya vaccine
- Live attenuated single dose
- 99% neutralizing Ab
- Caution immunocompromise + pregnancy
å¿
è â Chronic Chikungunya Arthritis Treatment
- NSAIDs + DMARDs (methotrexate, HCQ, sulfasalazine)
- Anti-TNF refractory